0001104659-14-074840.txt : 20141029
0001104659-14-074840.hdr.sgml : 20141029
20141029161609
ACCESSION NUMBER: 0001104659-14-074840
CONFORMED SUBMISSION TYPE: 3/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20141021
FILED AS OF DATE: 20141029
DATE AS OF CHANGE: 20141029
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PROTEON THERAPEUTICS INC
CENTRAL INDEX KEY: 0001359931
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 WEST STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 781-890-0102
MAIL ADDRESS:
STREET 1: 200 WEST STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Burke Steven Keith
CENTRAL INDEX KEY: 0001619834
FILING VALUES:
FORM TYPE: 3/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36694
FILM NUMBER: 141180385
MAIL ADDRESS:
STREET 1: 82 WILLIS ROAD
CITY: SUDBURY
STATE: MA
ZIP: 01776
3/A
1
a3a.xml
3/A
X0206
3/A
2014-10-21
2014-10-21
0
0001359931
PROTEON THERAPEUTICS INC
PRTO
0001619834
Burke Steven Keith
C/O PROTEON THERAPEUTICS
200 WEST STREET
WALTHAM
MA
02451
0
1
0
0
SVP and Chief Medical Officer
Common Stock
30411
D
Stock Option (Right to Buy)
2.39
2017-09-10
Common Stock
12287
D
Stock Option (Right to Buy)
3.18
2019-06-19
Common Stock
14898
D
Stock Option (Right to Buy)
1.27
2021-10-26
Common Stock
57934
D
Stock Option (Right to Buy)
4.92
2024-06-23
Common Stock
71218
D
Stock Option (Right to Buy)
4.92
2024-06-23
Common Stock
10696
D
Reflects a 1-for-15.87 reverse stock split effected on October 6, 2014.
The shares underlying these options are fully vested.
This option is fully exercisable prior to its vesting, subject to a repurchase right held by the Issuer on the shares underlying this option that lapses (based on the original option vesting schedule) in equal quarterly installments over four years.
This option is fully exercisable prior to its vesting, subject to a repurchase right held by the Issuer on the shares underlying this option that lapses (based on the original option vesting schedule) 25% on the first anniversary of the grant date and the remaining shares in equal quarterly installments over the next three years.
/s/ Steven K. Burke
2014-10-28